Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF

Mario Barbagallo, Francesco Mattace-Raso, Anna Kearney-Schwartz, Nicola Ferrara, Nicola Veronese, Regina Roller-Wirnsberger, Tuomo Nieminen, Elisabetta Canepa, Laura Pikkarainen, Nicolas Berg, Heidi Gruner, Pedro Marques Da Silva, Gil Gregorio Pedro, Timo Strandberg, Stefania Maggi, Philipp Bahrmann, Krzyszof Rewiuk, Juhani Rossinen, Peter Olexa, Alfonso Cruz-JentoftAlessandra Argusti, Mario Durando, Eva Topinkova, Hana Matejovska-Kubesova, Maria Cristina Polidori, Giovanni Ruotolo, Mario Bò, Mario Barbagallo, Nicolò Marchionni, Alberto Pilotto, Hans Jurgen Heppner

Risultato della ricerca: Article

Abstract

Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with different treatments for AF (no treatment vs oral anticoagulants) and differences in the main outcomes, i.e., mortality, major thromboembolic events and side effects. Materials and methods: Older hospitalized patients (age ≥ 65 years) with non-valvular AF will be consecutively enrolled in an European, cross-national, prospective, observational study. At baseline, functional and clinical information will be collected to calculate the MPI, CHA2DS2-VASc score, HAS-BLED score, pharmacological treatments (and the compliance during follow-up) and main and secondary diagnoses. During the 12-month follow-up period, information on survival, major thromboembolic events and major bleeding will be collected. For these aims, a sample size of 3000 people was deemed as sufficient. Conclusions: The EUROSAF study has the main objective of evaluating in a population of hospitalized older subjects with AF the clinical benefit/risk ratio of the oral anticoagulant treatments in terms of mortality, major thromboembolic events and bleeding side-effects, giving important information regarding the appropriate prescription of anticoagulant therapy in this population. ClinicalTrials.gov Identifier: NCT02973984.
Lingua originaleEnglish
pagine (da-a)149-154
Numero di pagine6
RivistaEuropean Geriatric Medicine
Volume9
Stato di pubblicazionePublished - 2018

Fingerprint

Anticoagulants
Atrial Fibrillation
Mortality
Observational Studies
Prescriptions
Therapeutics
Prospective Studies
Hemorrhage
Independent Living
Sample Size
Calibration
Population
Compliance
Odds Ratio
Pharmacology
Survival

All Science Journal Classification (ASJC) codes

  • Gerontology
  • Geriatrics and Gerontology

Cita questo

Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF. / Barbagallo, Mario; Mattace-Raso, Francesco; Kearney-Schwartz, Anna; Ferrara, Nicola; Veronese, Nicola; Roller-Wirnsberger, Regina; Nieminen, Tuomo; Canepa, Elisabetta; Pikkarainen, Laura; Berg, Nicolas; Gruner, Heidi; Da Silva, Pedro Marques; Pedro, Gil Gregorio; Strandberg, Timo; Maggi, Stefania; Bahrmann, Philipp; Rewiuk, Krzyszof; Rossinen, Juhani; Olexa, Peter; Cruz-Jentoft, Alfonso; Argusti, Alessandra; Durando, Mario; Topinkova, Eva; Matejovska-Kubesova, Hana; Polidori, Maria Cristina; Ruotolo, Giovanni; Bò, Mario; Barbagallo, Mario; Marchionni, Nicolò; Pilotto, Alberto; Heppner, Hans Jurgen.

In: European Geriatric Medicine, Vol. 9, 2018, pag. 149-154.

Risultato della ricerca: Article

Barbagallo, M, Mattace-Raso, F, Kearney-Schwartz, A, Ferrara, N, Veronese, N, Roller-Wirnsberger, R, Nieminen, T, Canepa, E, Pikkarainen, L, Berg, N, Gruner, H, Da Silva, PM, Pedro, GG, Strandberg, T, Maggi, S, Bahrmann, P, Rewiuk, K, Rossinen, J, Olexa, P, Cruz-Jentoft, A, Argusti, A, Durando, M, Topinkova, E, Matejovska-Kubesova, H, Polidori, MC, Ruotolo, G, Bò, M, Barbagallo, M, Marchionni, N, Pilotto, A & Heppner, HJ 2018, 'Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF', European Geriatric Medicine, vol. 9, pagg. 149-154.
Barbagallo, Mario ; Mattace-Raso, Francesco ; Kearney-Schwartz, Anna ; Ferrara, Nicola ; Veronese, Nicola ; Roller-Wirnsberger, Regina ; Nieminen, Tuomo ; Canepa, Elisabetta ; Pikkarainen, Laura ; Berg, Nicolas ; Gruner, Heidi ; Da Silva, Pedro Marques ; Pedro, Gil Gregorio ; Strandberg, Timo ; Maggi, Stefania ; Bahrmann, Philipp ; Rewiuk, Krzyszof ; Rossinen, Juhani ; Olexa, Peter ; Cruz-Jentoft, Alfonso ; Argusti, Alessandra ; Durando, Mario ; Topinkova, Eva ; Matejovska-Kubesova, Hana ; Polidori, Maria Cristina ; Ruotolo, Giovanni ; Bò, Mario ; Barbagallo, Mario ; Marchionni, Nicolò ; Pilotto, Alberto ; Heppner, Hans Jurgen. / Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF. In: European Geriatric Medicine. 2018 ; Vol. 9. pagg. 149-154.
@article{c60664da1b984f8c933103245d7c01fc,
title = "Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF",
abstract = "Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with different treatments for AF (no treatment vs oral anticoagulants) and differences in the main outcomes, i.e., mortality, major thromboembolic events and side effects. Materials and methods: Older hospitalized patients (age ≥ 65 years) with non-valvular AF will be consecutively enrolled in an European, cross-national, prospective, observational study. At baseline, functional and clinical information will be collected to calculate the MPI, CHA2DS2-VASc score, HAS-BLED score, pharmacological treatments (and the compliance during follow-up) and main and secondary diagnoses. During the 12-month follow-up period, information on survival, major thromboembolic events and major bleeding will be collected. For these aims, a sample size of 3000 people was deemed as sufficient. Conclusions: The EUROSAF study has the main objective of evaluating in a population of hospitalized older subjects with AF the clinical benefit/risk ratio of the oral anticoagulant treatments in terms of mortality, major thromboembolic events and bleeding side-effects, giving important information regarding the appropriate prescription of anticoagulant therapy in this population. ClinicalTrials.gov Identifier: NCT02973984.",
keywords = "Anticoagulants, Atrial Fibrillation, Elderly, Frailty, Geriatrics and Gerontology, Gerontology, Muldimensional Prognostic Index",
author = "Mario Barbagallo and Francesco Mattace-Raso and Anna Kearney-Schwartz and Nicola Ferrara and Nicola Veronese and Regina Roller-Wirnsberger and Tuomo Nieminen and Elisabetta Canepa and Laura Pikkarainen and Nicolas Berg and Heidi Gruner and {Da Silva}, {Pedro Marques} and Pedro, {Gil Gregorio} and Timo Strandberg and Stefania Maggi and Philipp Bahrmann and Krzyszof Rewiuk and Juhani Rossinen and Peter Olexa and Alfonso Cruz-Jentoft and Alessandra Argusti and Mario Durando and Eva Topinkova and Hana Matejovska-Kubesova and Polidori, {Maria Cristina} and Giovanni Ruotolo and Mario B{\`o} and Mario Barbagallo and Nicol{\`o} Marchionni and Alberto Pilotto and Heppner, {Hans Jurgen}",
year = "2018",
language = "English",
volume = "9",
pages = "149--154",
journal = "European Geriatric Medicine",
issn = "1878-7649",
publisher = "Elsevier Masson",

}

TY - JOUR

T1 - Evaluating the effectiveness and risks of oral anticoagulant treatments in multimorbid frail older subjects with atrial fibrillation using the multidimensional prognostic index: the EURopean study of older subjects with atrial fibrillation—EUROSAF

AU - Barbagallo, Mario

AU - Mattace-Raso, Francesco

AU - Kearney-Schwartz, Anna

AU - Ferrara, Nicola

AU - Veronese, Nicola

AU - Roller-Wirnsberger, Regina

AU - Nieminen, Tuomo

AU - Canepa, Elisabetta

AU - Pikkarainen, Laura

AU - Berg, Nicolas

AU - Gruner, Heidi

AU - Da Silva, Pedro Marques

AU - Pedro, Gil Gregorio

AU - Strandberg, Timo

AU - Maggi, Stefania

AU - Bahrmann, Philipp

AU - Rewiuk, Krzyszof

AU - Rossinen, Juhani

AU - Olexa, Peter

AU - Cruz-Jentoft, Alfonso

AU - Argusti, Alessandra

AU - Durando, Mario

AU - Topinkova, Eva

AU - Matejovska-Kubesova, Hana

AU - Polidori, Maria Cristina

AU - Ruotolo, Giovanni

AU - Bò, Mario

AU - Barbagallo, Mario

AU - Marchionni, Nicolò

AU - Pilotto, Alberto

AU - Heppner, Hans Jurgen

PY - 2018

Y1 - 2018

N2 - Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with different treatments for AF (no treatment vs oral anticoagulants) and differences in the main outcomes, i.e., mortality, major thromboembolic events and side effects. Materials and methods: Older hospitalized patients (age ≥ 65 years) with non-valvular AF will be consecutively enrolled in an European, cross-national, prospective, observational study. At baseline, functional and clinical information will be collected to calculate the MPI, CHA2DS2-VASc score, HAS-BLED score, pharmacological treatments (and the compliance during follow-up) and main and secondary diagnoses. During the 12-month follow-up period, information on survival, major thromboembolic events and major bleeding will be collected. For these aims, a sample size of 3000 people was deemed as sufficient. Conclusions: The EUROSAF study has the main objective of evaluating in a population of hospitalized older subjects with AF the clinical benefit/risk ratio of the oral anticoagulant treatments in terms of mortality, major thromboembolic events and bleeding side-effects, giving important information regarding the appropriate prescription of anticoagulant therapy in this population. ClinicalTrials.gov Identifier: NCT02973984.

AB - Background: Previous studies suggested that a different risk of mortality may influence the oral anticoagulant prescription in older patients with atrial fibrillation (AF). Recently, the Multidimensional Prognostic Index (MPI) demonstrated a high grade of accuracy, calibration and feasibility to predict mortality in hospitalized and community-dwelling older people. Prognostic information, as calculated by the MPI, however, is not included in the decision algorithm of treatments in older patients with AF Purpose: The aim of this international multicenter prospective observational study was to evaluate whether a different prognostic profile, as determined by the MPI, is associated with different treatments for AF (no treatment vs oral anticoagulants) and differences in the main outcomes, i.e., mortality, major thromboembolic events and side effects. Materials and methods: Older hospitalized patients (age ≥ 65 years) with non-valvular AF will be consecutively enrolled in an European, cross-national, prospective, observational study. At baseline, functional and clinical information will be collected to calculate the MPI, CHA2DS2-VASc score, HAS-BLED score, pharmacological treatments (and the compliance during follow-up) and main and secondary diagnoses. During the 12-month follow-up period, information on survival, major thromboembolic events and major bleeding will be collected. For these aims, a sample size of 3000 people was deemed as sufficient. Conclusions: The EUROSAF study has the main objective of evaluating in a population of hospitalized older subjects with AF the clinical benefit/risk ratio of the oral anticoagulant treatments in terms of mortality, major thromboembolic events and bleeding side-effects, giving important information regarding the appropriate prescription of anticoagulant therapy in this population. ClinicalTrials.gov Identifier: NCT02973984.

KW - Anticoagulants

KW - Atrial Fibrillation

KW - Elderly

KW - Frailty

KW - Geriatrics and Gerontology

KW - Gerontology

KW - Muldimensional Prognostic Index

UR - http://hdl.handle.net/10447/297007

UR - http://www.springer.com/journal/41999

M3 - Article

VL - 9

SP - 149

EP - 154

JO - European Geriatric Medicine

JF - European Geriatric Medicine

SN - 1878-7649

ER -